Navigation Links
Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
Date:10/4/2011

WEST LAFAYETTE, Ind., Oct. 4, 2011 /PRNewswire/ -- Kylin Therapeutics, Inc., a leading second-generation RNAi company, announced today that it has received a notice of allowance from United States Patent and Trademark Office (USPTO) for its second U.S. patent application. This newly allowed patent broadly covers new therapeutic RNA technology, as well as expanded areas on Kylin's proprietary nanoparticle technology platform, "pRNA" ("packaging RNA"). This new intellectual property covers multi-valent RNA structures broadly encompassing: tissue targeting, aptamer binding, receptor-mediated endocytosis, and RNA interference. "We continue to be gratified that the USPTO recognizes pRNA as an entirely unique platform in the crowded RNAi intellectual property space," said J. Eric Davis, J.D., President and Chief Executive Officer of Kylin Therapeutics, Inc.

Upon issuance, this will be Kylin's second U.S. patent. Along with its other issued and granted pRNA patents in Europe, Australia, and the United States, Kylin believes that this seminal patent family represents rare "new ground" in the field of RNAi and the delivery of therapeutic RNA. Kylin has a total of five patent families, with several other applications in the pipeline. "The unexpected, pharmacologically robust nature of the pRNA platform continues to allow Kylin to claim more ground in areas such as RNAi and tissue-specific targeting," said Homer Pearce, Ph.D., Director and Chairman of Kylin's Scientific Advisory Board.

Kylin's pRNA intellectual property estate is based upon the innovative discoveries of Peixuan Guo, Ph.D., and others at Kylin, on the design and creation of novel, therapeutically relevant RNA molecules. These molecules can be engineered as RNA multiplexes that function as RNAi-inducing DICER substrates and tissue-targeting modalities, and they can be used systemically and discretely without additional delivery components. Kylin has continued and expanded upon the work of Dr. Gu
'/>"/>

SOURCE Kylin Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Skyline Diagnostics Establishes Research Collaboration With Janssen
2. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
4. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
5. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
6. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
7. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
8. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
9. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
10. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
11. PTC Therapeutics and Genzyme Announce Restructuring of Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... , Aug. 28, 2014  Next month, executives from clinical ... key industry events beginning with Patient-Centered Clinical Trials 2014 ... Boston , September 4-5. Patient recruitment experts ... Aaron Fleishman will share insights on the benefits ... variety of tactics – from media to mobile apps – ...
(Date:8/28/2014)... 28, 2014  Armetheon, Inc. ( www.armetheon.com ), ... to late-stage cardiovascular drug candidates, today announced that ... round of financing. The Series A round was ... with participation from investors that included Atheneos Capital ... Larry Hsu , the founder of Impax ...
(Date:8/28/2014)... 28, 2014 A new market ... world is available from Strategic Consulting, Inc., the ... Industrial Microbiology Market Review, Fourth Edition: Global Review ... (IMMR—4) tracks and compares microbiology test volumes, market ... Europe and Asia, and forecasts future volumes and ...
(Date:8/28/2014)... August 28, 2014 Supplementing their ... a promotion for Eppendorf Safe Lock Centrifuge ... purchase the highest quality tubes at an affordable ... for customers doing chemical, medical, pharmaceutical, and life ... are not regularly able to afford Eppendorf products. ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... Company Provides R&D Pipeline Update -, IRVINE, Calif., March ... financial results for the year ended,December 31, 2007. ISTA reported ... 2007, a 78% increase over the full-year 2006 results of,$33.0 ... 56% over,the fourth quarter of 2006., "2007 was a ...
... WEST CHESTER, Pa., March 6 VWR Funding, Inc., the,parent company of VWR International, LLC, ... its fourth quarter and year-end financial results., Who: ... Jack L. Wyszomierski, Executive ... Financial Officer, When: ...
... Chemistry Testing Market, FULLERTON, Calif., March ... ) announced today that it has launched ... an integrated work cell which,consolidates chemistry and ... addition to the company,s work cell family,combines ...
Cached Biology Technology:ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 2ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 3ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 4ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 5ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 6ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 7ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results 8VWR Funding, Inc. to Hold Fourth Quarter and Year-End 2007 Financial Results Conference Call 2Beckman Coulter Releases the High-Volume UniCel(R) DxC 880i Integrated Work Cell 2
(Date:8/28/2014)... million kilometres of new roads will be built worldwide ... Earth,s last wildernesses, where they bring an influx of ... an ambitious study has created a ,global roadmap, for ... balance the competing demands of development and environmental protection. ... that estimates that natural importance of ecosystems and a ...
(Date:8/28/2014)... to alert the world to Global Warming, has called ... stored underground. He says that Carbon Capture, combined with ... to avoid global warming getting out of control over ... York) made the call during his presentation to the ... are meeting to discuss Carbon Capture and Storage. ...
(Date:8/28/2014)... at Ludwig-Maximilians-Universitaet (LMU) in Munich have assigned a ... of predatory arthropods. These animals lived in shallow ... related forms found in Jurassic strata. , ... shallow marine habitat and were fossilized some 435 ... denizens of the Silurian seas although they ...
Breaking Biology News(10 mins):Study shows where on the planet new roads should and should not go 2Study shows where on the planet new roads should and should not go 3Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2Paleontology: Oldest representative of a weird arthropod group 2
... nanotechnology fanciers suggest that, like proverbial birds of ... or clump together. This tendency, they ... manufacturing increases and the number of nanotechnology-enabled products ... Maynard, chief science advisor to the Project on ...
... completing the first large-scale report sequencing breast and colon ... studied the vast majority of protein-coding genes which now ... mutated in relatively few cancers. Their report, published ... indicates that while little is known about these less-commonly ...
... a reality today, but how can we find out about ... a full record of the Earths climate for several hundred ... that can be taken to the lab for analysis. Incredibly, ... Antarctic regions, and a European Science Foundation programme has a ...
Cached Biology News:Nanoparticle exposures happen, says expert 2Genome update defines landscape of breast and colon cancers 2Genome update defines landscape of breast and colon cancers 3European lead in reading past climates from ice cores 2European lead in reading past climates from ice cores 3
... Cloning Kits are designed to speed up the ... PCR products, regardless of sequence or type of ... including those that are difficult to clone by ... unstable or code for potentially detrimental proteins can ...
... Blunt-Ended PCR Cloning Kit, 40 ... efficient cloning of all PCR products ... TA cloning approaches by offering consistently ... as 25-fold more positive clones.Amplicons generated ...
Antibodies were affinity purified using epitopes specific to XLF immobilized on solid support....
... Immunogen: Synthetic peptide derived from ... protein (chromosome 17 open reading frame 37 ... for the C35 protein. On Western blots ... kDa band. Reactivity: Human (positive control: ...
Biology Products: